Mad Money' host Jim Cramer weighs in on stocks including: Deere, Arm Holdings, Vital Farms, and Bristol-Myers Squibb ... Gene Hackman's wife surged in Arizona in 2024 10 Things About Living ...

Tremelimumab has been approved by the FDA in the US for use in tandem with AZ's PD-L1 inhibitor Imfinzi ... in the class to be approved after Bristol-Myers Squibb's well-established Yervoy ...

Bristol-Myers Squibb has won FDA approval for the first ... ballpark as the Opdivo/Yervoy combination for melanoma. BMS sues AZ, claiming Imfinzi infringes Opdivo patents BMS, meanwhile, has ...

Orthoscan, Inc., proudly announces the launch of VERSA, a groundbreaking mini C-arm for clinical imaging, debuting at the American Academy of Orthopaedic Surgeons (AAOS) annual meeting in San Diego, ...

For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...

Curatis Holding (SIX:CURN) announces today the formation of an Advisory Board comprised of four internationally recognized experts across multiple medical and scientific disciplines. The board brings ...

ReviveMed's AI platform analyzes metabolite data, revealing insights into diseases and streamlining drug development for ...

Correspondence to Dr. Rish K Pai, Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, Arizona 85259, USA; pai.rish{at}mayo.edu The Robarts Histopathology Index (RHI) is a ...

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

The stock's fall snapped a four-day winning streak.

Bristol Myers Squibb (BMY) closed the most recent trading day at $60.18, moving +0.6% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 1.78%.